CARMEN-LC05
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
- NCT04524689 ↗
- Terminated
- Sanofi
- Focused
We haven't built an HCP commentary report on CARMEN-LC05 (tusamitamab ravtansine plus pembrolizumab; tusamitamab ravtansine plus pembrolizumab plus platinum-based chemotherapy; tusamitamab ravtansine plus pembrolizumab plus platinum-based chemotherapy plus pemetrexed in CEACAM5-positive advanced/metastatic non-squamous non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CARMEN-LC05 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Interventions
- SAR408701 (Tusamitamab ravtansine); Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Tusamitamab ravtasine 150 mg/m^2 + Pembrolizumab · Experimental
- Tusamitamab ravtasine 170 mg/m^2 + Pembrolizumab · Experimental
- Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin · Experimental
- Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin · Experimental
- Tusamitamab ravtansine 150 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed · Experimental
- Tusamitamab ravtansine 170 mg/m^2 + Pembrolizumab + carboplatin or cisplatin + pemetrexed · Experimental
- Enrollment
- 57
- Primary outcomes
- All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs)
- Doublet Cohort: Objective Response Rate (ORR)
- Quadruplet Cohort: Objective Response Rate
- Sponsor
- Sanofi
- Start
- Oct 26, 2020
- Primary completion
- Mar 12, 2024
- Results posted
- Yes
- Registry record
- NCT04524689 · updated Oct 29, 2025